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Summary
The PI3K/PTEN/Akt signal transduction pathway plays a key role in many tumors. Downstream targets of this pathway
include the Forkhead family of transcription factors (FOXO1a, FOXO3a, FOXO4). In PTEN null cells, FOXO1a is inactivated
by PI3K-dependent phosphorylation and mislocalization to the cytoplasm, yet still undergoes nucleocytoplasmic shuttling.
Since forcible localization of FOXO1a to the nucleus can reverse tumorigenicity of PTEN null cells, a high-content, chemical
genetic screen for inhibitors of FOXO1a nuclear export was performed. The compounds detected in the primary screen
were retested in secondary assays, and structure-function relationships were identified. Novel general export inhibitors
were found that react with CRM1 as well as a number of compounds that inhibit PI3K/Akt signaling, among which are
included multiple antagonists of calmodulin signaling.
Introduction del Peso et al., 1999; Kops et al., 1999; Rena et al., 1999;
Takaishi et al., 1999; Tang et al., 1999). These transcription
The PTEN lipid phosphatase acts as a tumor suppressor and factors are involved in negatively regulating cell cycle progres-
negative regulator of PI3K/Akt-driven cell growth and survival. sion and cell survival (Medema et al., 2000; Nakamura et al.,
It antagonizes PI3K signal transduction by dephosphorylating 2000). The phosphorylation state and subsequent subcellular
the PI3K phosphorylation products, PI3,4,P2 (PIP2) and PI3, localization help regulate the activity of these factors. In PTEN
4,5,P3 (PIP3) (Maehama and Dixon, 1998). Mutations in PTEN mutant cells, increased PIP3 levels result in constitutive activa-
have been implicated in Cowden Disease—a hereditary disease tion of Akt, which phosphorylates FOXO transcription factors at
marked by a high predisposition for breast and thyroid cancers multiple sites, preventing transcriptional activity and promoting
(Vazquez and Sellers, 2000). In addition, PTEN deficiency has nuclear export (Biggs et al., 1999; Brownawell et al., 2001; Bru-
been found in cancers such as glioblastoma multiforme, endo-
net et al., 1999; Rena et al., 1999). In addition to Akt, there ismetrial and prostate cancer, melanoma, and renal cell carci-
growing evidence that other kinases such as SGK, DYRK1A,noma (Kondo et al., 2001; Kong et al., 1997; Wang et al., 1997).
CK1, and PAK1 are involved in FOXO phosphorylation and ex-Inhibition of the PI3K/Akt signaling pathway in PTEN null cells
port (Brunet et al., 2001; Mazumdar and Kumar, 2003; Rena etcan control aberrant cell growth.
al., 2002; Woods et al., 2001). Phosphorylation of the FOXOMammalian members of the FOXO or Forkhead family of
transcription factors facilitates binding with 14-3-3 proteins andtranscription factors include FOXO1a, FOXO3a, and FOXO4
export out of the nucleus (Brunet et al., 2002; Rena et al., 2001).(also known as FKHR, FKHRL1, and AFX, repectively), each of
which are phosphorylation targets of Akt (Brunet et al., 1999; Nuclear export of these factors is mediated by the export recep-
S I G N I F I C A N C E
The PTEN gene is mutated in a significant number of tumors, leading to the loss of PTEN lipid phosphatase activity and constitutive
activation of PI3K/Akt signaling. It is currently unclear as to where in this pathway one might seek to intervene with a small molecule
inhibitor and whether novel targets for therapy might exist. Surprisingly, an unbiased cell-based, small molecule screen based on
FOXO1a localization led to the discovery of several inhibitors, including those that inhibit calmodulin. These data suggest that this
approach can lead to the identification of novel lead compounds and targets for therapeutic development against tumors in which
the PI3K/Akt pathway is aberrantly activated.
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tor CRM1 (Biggs et al., 1999; Brownawell et al., 2001; Brunet ment with the nuclear export inhibitor, LMB, also resulted in
FOXO1a nuclear sequestration (Figure 1B). As a negative con-et al., 2002).
trol, DMSO did not affect FOXO1a subcellular localization (Fig-Many proteins that exit the nucleus contain short stretches
ure 1B). These data indicate that FOXO1a shuttles betweenof amino acids that act as nuclear export sequences (NESs)
the nucleus and cytoplasm in a PI3K- and CRM1-dependent(Gerace, 1995). The NES-bearing protein is bound in the nucleus
manner and that the intracellular shuttling of FOXO1a is anby the nuclear export receptor, CRM1, and escorted to the
appropriate measure of both PI3K/Akt pathway activation andcytoplasm via a channel formed by the nuclear pore complex
CRM1 or possibly other nuclear export factor activation (Fig-(NPC) (Fornerod et al., 1997; Fukuda et al., 1997; Ossareh-
ure 1C).Nazari et al., 1997; Stade et al., 1997). Leptomycin B (LMB)
Using localization of FOXO1a as a visual assay, 18,000inhibits protein nuclear export mediated by CRM1 (Kudo et al.,
compounds from the NCI Structural Diversity Set, ChemBridge1998). Isolated from Streptomyces, LMB covalently modifies
DiverSetE, and a small collection of NCI marine extracts wereCRM1 at a specific cysteine residue by a Michael-type addition
tested for their ability to relocalize FOXO1a to the nucleus inwhich inhibits binding of CRM1 with the NES-containing cargo
PTEN null cells. Ad-FKHR-infected 786-O cells were grown on(Kudo et al., 1999). Thus, the NES-containing cargo becomes
384-well, clear-bottom plates before library compounds weretrapped in the nucleus. FOXO transcription factors are among
transferred onto cells by a 384-pin array robot. Cells were fixedthose proteins whose nuclear export is inhibited by LMB (Biggs
and stained after 1 hr treatment and FOXO1a localization deter-et al., 1999; Brownawell et al., 2001; Brunet et al., 2002).
mined by automated fluorescence microscopy. Eighty-nineWhen the three known Akt phosphorylation sites on FOXO1a
compounds relocalized FOXO1a to the nucleus in this primary
are mutated to alanine, this AAA mutant can no longer undergo
screen. Based on availability and potency, 42 total compounds
phosphorylation and accumulates in the nucleus, allowing re- were obtained for further characterization (seven from the NCI
constitution of FOXO1a activity to PTEN null cells (Nakamura Structural Diversity Set, 34 from ChemBridge DiverSetE, and
et al., 2000; Ramaswamy et al., 1999). Such reconstitution ar- one from the NCI marine extracts).
rests cells in G1, inhibits soft-agar growth, and inhibits xenograft
growth in nude mice, thus recapitulating many aspects of Identification of general export inhibitors
PTEN-mediated tumor suppression (Nakamura et al., 2000; Ra- In order to distinguish compounds that might target the general
maswamy et al., 1999). Small molecules that block FOXO1a nuclear export machinery from those that target components
export could target members of the general protein transport of the PI3K/Akt/FOXO1a signaling pathway, each of the 42 small
machinery and inhibit proteins other than CRM1. In addition, molecules identified in the primary screen was tested for the
small molecules may act as novel kinase inhibitors, revealing ability to block the export of HIV Rev, a protein known to undergo
new aspects of FOXO1a signal transduction, and serve as pre- CRM1-dependent nucleocytoplasmic transport (Wolff et al.,
liminary anticancer therapeutics. 1997). Here, compounds were serially diluted from 40 M and
The present study describes a cell-based, chemical genetic added to U2OS cells stably expressing a RevGFP fusion protein
screen using FOXO1a subcellular localization as the readout. containing the NES from PKI. As previously shown, this RevGFP
fusion localizes to the cytoplasm at steady state (Figure 2A)Two classes of compounds that inhibit FOXO1a nuclear export
(Henderson and Eleftheriou, 2000), and treatment of these cellswere identified: (1) compounds that target the general nuclear
with LMB leads to accumulation of RevGFP in the nucleolustransport machinery and (2) compounds specific to the PI3K/
(Figure 2A). Similarly, 19 of the initial 42 compounds blockedAkt/FOXO1a signaling pathway. Several compounds in the first
RevGFP export and are thus described hereforeward as “gen-class possess electrophilic moieties that most likely alkylate
eral export inhibitors” (Figure 2B).Cys528 in CRM1 by a manner similar to the mode of action of
LMB. Compounds in the second class have been characterized
The general export inhibitors target Cys528 of CRM1further and implicate calmodulin as a mediator of FOXO1a
LMB blocks NES-mediated nuclear export by covalently modi-nucleocytoplasmic localization and regulation.
fying CRM1 at Cys528 in humans and Cys529 in S. pombe by
a Michael-type addition as illustrated in Figure 3A (Kudo et al.,Results
1999, 1998). To determine whether any of these novel general
export inhibitors similarly target the CRM1 Cys528 residue,A cell-based screen for FOXO1a nuclear
U2OS-RevGFP cells were transfected with a dominant-negativelocalization in PTEN null cells
CRM1 mutant expressing a Cys528Ser substitution. Cells ex-In order to identify novel nuclear transport inhibitors as well
pressing this mutant are viable and insensitive to LMB-mediated
as small molecules that target the PI3K/Akt/FOXO1a signaling
inhibition of nuclear export (Akakura et al., 2001) (Figure 3B).
pathway, a visual cell-based assay was developed that used Furthermore, cells are still sensitive to LMB when overexpress-
FOXO1a subcellular localization as the output. PTEN null, 786-O ing wild-type CRM1 (Akakura et al., 2001). Of the 19 general
renal carcinoma cells were infected with an adenovirus expressing export inhibitors, 11 were inactive in CRM1-Cys528Ser trans-
FLAG epitope tagged FOXO1a (Ad-FKHR). Cells were grown fected U2OS-RevGFP cells, suggesting that these compounds
for 24 hr after infection to allow for adequate expression of likely act by covalently modifying CRM1 at its reactive cysteine
FLAG-FKHR and then treated with compounds for 1 hr, followed residue (Figure 3C). Approximately 50% of total cells exhibited
by immunostaining and imaging. In these cells, as previously cytoplasmic RevGFP—reflective of the transfection efficiency—in
published, FOXO1a is constitutively localized to the cytoplasm contrast to 100% nucleolar RevGFP in nontransfected cells. As
(Figure 1A). In contrast, FOXO1a localizes to both the nucleus a control, cells were also transfected with wild-type CRM1 and
and cytoplasm in PTEN/ growing U2OS cells (Figure 1A). treated with the general export inhibitors. In these cells, the
Treatment of infected cells with the PI3K inhibitor, wortmannin, compounds blocked RevGFP export as they did in cells not
overexpressing CRM1, as previously exhibited with LMB (dataled to FOXO1a relocalization to the nucleus and, likewise, treat-
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Figure 1. FOXO1a subcellular localization and screening assay
A: PTEN/ 786-O cells or PTEN/ U2OS cells were infected with Ad-FKHR before FOXO1a cellular localization was visualized by immunofluorescence. In
786-O cells, FOXO1a is predominantly in the cytoplasm, whereas in U2OS cells, FOXO1a is both in the cytoplasm and nucleus. Nuclei were visualized by
staining with Hoechst 33258. At least 200 cells were counted and the percent of predominantly nuclear (N), nuclear and cytoplasmic (NC), and cytoplasmic
(C) cells were determined with standard errors.
B: FOXO1a relocalizes to the nucleus in Ad-FKHR infected 786-O cells after treatment with wortmannin (39 nM) or LMB (4 nM), but not with DMSO.
C: Hyperphosphorylation of FOXO1a, as a result of PI3K/Akt signal transduction, promotes FOXO1a export into the cytoplasm. Inhibition of any one of the
steps in the PI3K/Akt signaling pathway, as well as members of the nuclear export machinery, can lead to FOXO1a nuclear retention. PI3K phosphorylates
PI4P or PI4,5P2 and this reaction is reversed by the lipid phosphatase, PTEN. Upon PI3,4,5P3 formation, Akt is recruited to the membrane and can undergo
phosphorylation and activation by PDK1. FOXO1a is phosphorylated by an activated Akt, as well as other kinases, leading to binding with 14-3-3 and the
promotion of nuclear export by CRM1.
not shown). The results for the remaining eight compounds were cells containing the mutated CRM1 were transformed with a
reporter plasmid expressing GFP containing both an NLS andinconclusive in this assay. Thus, a second assay was developed
in yeast to address the mode of action of these small molecules. an NES (Taura et al., 1998). In wild-type yeast cells, this protein
shuttles between the nucleus and the cytoplasm, yet appearsS. cerevisiae are insensitive to LMB because the yeast CRM1
contains a threonine at the homologous cysteine position (Nev- mostly in the yeast cytoplasm (Figure 3D). Wild-type yeast cells
transformed with the NLS-NES-GFP reporter do not show accu-ille and Rosbash, 1999). Cells can be made LMB sensitive by
integration of a CRM1 mutant containing a Thr539Cys substitu- mulation of NLS-NES-GFP in the nucleus after treatment with
LMB (Figure 3D). Conversely, in yeast cells expressing thetion in place of the wild-type yeast CRM1 (Neville and Rosbash,
1999). Based on these observations, wild-type yeast cells and CRM1 Thr539Cys mutation, shuttling of NLS-NES-GFP is
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Figure 2. RevGFP export assay for general nu-
clear export inhibitors
A: U2OS cells stably expressing RevGFP were
treated with DMSO or LMB. At steady state,
RevGFP localizes to the cytoplasm in DMSO-
treated cells while undergoing nucleocytoplas-
mic shuttling. However, in the presence of LMB
(9.25 nM), RevGFP is trapped in the nucleoli due
to a block in export in all cells. Nuclei were visual-
ized by staining with Hoechst 33258.
B: U2OS-RevGFP cells were treated with all lead
compounds resulting in 19 inhibitors of RevGFP
export. Examples of five general export inhibitors
at 20 M trap RevGFP in the nucleoli of all cells
(%N  100) whereas the phenothiazine 17474Z
at 20 M does not (%N  0).
blocked upon treatment with LMB. (Figure 3D). The 19 general black). Thus all of the general export inhibitors exhibit properties
that likely explain the dependency of export inhibition on theexport inhibitors, when retested in this assay, each blocked
shuttling of NLS-NES-GFP in the humanized yeast. Thus, all CRM1 Cys528 residue.
appear to act through the CRM1 Cys528 residue (Figure 3E).
Pathway-specific FOXO1a export inhibitors
Twenty-three compounds, though inhibitors of FOXO1a export,Compound structures reveal their mode of action
Comparing the structures of the 19 general export inhibitors to failed to alter export of RevGFP, and thus are termed pathway-
or FOXO1a-specific. To determine whether such compoundsthe structure of LMB revealed, in eight compounds, an ,-unsat-
urated ketone or amide group that can likely undergo a Michael- were likely to act upstream or downstream of Akt, extracts were
prepared from 786-O cells after treatment with each of thetype addition with the sulfhydryl group on Cys528 (Figure 4A;
red). In addition, other compounds might undergo nucleophilic pathway-specific inhibitors or wortmannin, and phospho-Ser473-
Akt was detected by immunoblotting. Two inhibitors (5219657attack by the sulfhydryl group through a good halide leaving
group (Figure 4A; blue), or across a triple bond (Figure 4A; and B6-7-1) did not abolish phospho-Ser473-Akt levels similar
to DMSO and thus likely have targets downstream of Akt or ingreen), or might undergo rearrangement for further reactivity
(Figure 4A; pink). For three compounds, an obvious mechanism a separate synergistic pathway (Figures 5A and 6). However, 21
compounds inhibited Ser473-Akt phosphorylation with varyingwas not apparent though each was electrophilic (Figure 4A;
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Figure 3. Assay for small molecules that target CRM1 in U2OS-RevGFP cells and yeast
A: LMB inhibits CRM1-mediated export by covalently modifying Cys528 by a Michael-type addition.
B: U2OS-RevGFP cells were either treated with 9.25 nM LMB or first transfected with the CRM1-Cys528Ser mutant before treatment with LMB. LMB blocks
RevGFP export in nontransfected cells but does not block RevGFP export in cells expressing the CRM1-Cys528Ser mutant, resulting in about 50% cytoplasmic
cells. Nuclei were visualized by Hoechst 33258 staining.
C: U2OS-RevGFP cells transfected with CRM1-Cys528Ser were treated with all 19 of the general export inhibitors. Here are examples of six compounds at
20 M that do not block RevGFP export in cells expressing the CRM1 mutant, and thus target CRM1 at Cys528. About 50% of cells exhibited cytoplasmic
RevGFP.
D: Wild-type yeast cells and humanized, mutant LMB-sensitive yeast cells were transformed with the NLS-NES-GFP reporter. NLS-NES-GFP is found throughout
wild-type cells treated with either DMSO or 9.25 nM LMB. However, in CRM1 mutant, LMB-sensitive cells, 9.25 nM LMB treatment results in the nuclear
accumulation of NLS-NES-GFP. DMSO treatment results in the reporter found throughout the cell. Nuclei were visualized by staining with DAPI.
E: All 19 of the general export inhibitors target CRM1 at the reactive cysteine residue when tested in wild-type and CRM1 mutant, LMB-sensitive yeast cells.
Examples of various compounds (all at 20 M) show NLS-NES-GFP localization throughout the cell in wild-type yeast and nuclear localization in CRM1
mutant cells. Arrows point to nuclear retention and nuclei were stained with DAPI for comparison.
efficacy. Phospho-Thr308 Akt was also probed and all com- Akt nuclear localization was investigated in 786-O cells
treated with pathway-specific inhibitors. If FOXO1a is phosphor-pounds that blocked Ser473 phosphorylation similarly blocked
Thr308 phosphorylation (Figures 5A and 6). As a control, treat- ylated by Akt in the nucleus, then it is possible that any com-
pounds decreasing Akt phosphorylation levels and trappingment of cells with the general export inhibitors did not substan-
tially alter Akt phosphorylation when tested at 20 M, though FOXO1a in the nucleus might also result in the inhibition of
FOXO1a phosphorylation by Akt mislocalization. Interestingly,three exhibited modest inhibition at 40M (Figure 6 and data not
shown). Phospho-Ser255/Thr256 SGK levels were also probed treatment with the pathway-specific inhibitors did not affect Akt
nuclear localization and overexpressed Akt as well as endoge-revealing two compounds that significantly inhibited SGK phos-
phorylation (Figure 6). The two compounds that showed an nous Akt was found throughout the cell (data not shown).
The pathway-specific compounds were next validated in aeffect, 5175309 and 5217339, might either exhibit less specific-
ity or perhaps affect a parallel pathway leading to SGK and second assay in which FOXO1a localization is constitutively
cytoplasmic based on expression of activated PI3K. Here, hu-FOXO1a phosphorylation.
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Figure 4. Structures of all lead compounds obtained for further characterization
A: General export inhibitors can covalently modify CRM1 like LMB either through an ,-unsaturated ketone or amide as shown by compounds highlighted
in red. Another method might be through the substitution of a good leaving group as shown by compounds highlighted in blue. Green highlighted
compounds contain a triple bond, which may undergo nucleophilic addition. Compounds in pink might undergo rearrangement for further reactivity.
B: Structures of PI3K/Akt/FOXO1a specific inhibitors. Compounds in red belong to the structural family of phenothiazines. Several compounds contain planar
heterocyles and may target the ATP binding sites of kinases. B6-7-1, in pink, was isolated from marine sponge extract.
man mammary epithelial cells (HMECs) containing either vector pounds have targets upstream of PI3K (Figures 5B and 6). Wort-
mannin and twelve pathway-specific inhibitors sequesteredalone or stably expressing a membrane-targeted and, hence,
constitutively active p110 subunit of PI3K (HMEC-Myr-p110) FOXO1a in the nucleus in both the vector and HMEC-Myr-p110
cells and thus likely act downstream of PI3K (Figures 5B and 6).(Zhao et al., 2003) were infected with Ad-FKHR. FOXO1a local-
ization was then determined by immunofluorescence after treat- In order to determine whether structure-activity relation-
ships existed with respect to these defined phenotypes, thement for 1 hr with each pathway-specific compound. In both
cell types, FOXO1a is cytoplasmic. Thus the vector cells serve structures of all pathway-specific inhibitors were examined.
Several of these compounds contain planar heterocycles thatas a positive control for inhibition by a compound at any point
along the PI3K pathway as well as a positive control for cell- might target the ATP binding sites of kinases. Examples include
benzimidazoles (5217490, 5233705), an indole (5107360), a car-specific drug metabolic properties such as cell permeability.
Nine compounds that scored repeatedly in 786-O cells failed bazole (5236848), hexahydrocarbazoles (5137877, 5271325), a
quinazoline (5175309), a dihydrophenanthroline (5213337), ato score in the vector control cells, and thus their position in
the pathway with respect to PI3K could not be formally estab- benzoxazole (5107769), benzofurans (5219657, 5160096), and
a dibenzofuran (89110Q) (Figure 4B). B6-7-1, from a marinelished in this assay (Figures 5B and 6). Two compounds
(89110Q, 293046M) blocked FOXO1a export in control cells, sponge extract, is an amino acid derived, novel bromotyrosine
derivative (Figure 4B; pink).but not in HMEC-Myr-p110 cells, suggesting that these com-
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Figure 5. Most pathway-specific inhibitors de-
crease phospho-Ser473 and phospho-Thr308 Akt
levels in 786-O cells, and block FKHR export in
HMEC-Myr-p110 cells
A: Cell extracts were made from 786-O cells after
treatment with pathway-specific compounds for
1 hr (all at 20 M unless otherwise noted), and
then immunoblotted with phospho-Akt and pan
Akt antibodies.
B: FOXO1a localization in HMECs stably express-
ing Myr-p110 or vector control. HMECs were in-
fected with Ad-FKHR and treated with pathway-
specific compounds for 1 hr. Treatment with
DMSO resulted in cytoplasmic FOXO1a in both
HMEC-vector and HMEC-Myr-p110 cells. Treat-
ment with 20 M wortmannin, 40 M trifluopera-
zine (17474Z), and 5 M B6-7-1 results in nuclear
FOXO1a in both cell types. Compound 293046M
(80 M) is an example of an inhibitor that causes
FOXO1a nuclear localization in vector cells but
not in Myr-p110 cells. Compound 5219657 (80
M) is an example of an inhibitor that blocks
FOXO1a export in neither cell types.
C: Compounds that trap FOXO1a in the nucleus
in Myr-p110 cells target at or downstream of
PI3K. Compounds that target upstream of PI3K
block FOXO1a export in HMEC-vector cells but
not in HMEC-Myr-p110 cells.
Phenothiazines—a class within the broader class of phenothiazines, additional phenothiazines
including chlorpromazine, prochlorperazine, fluphenazine, andthe pathway-specific inhibitors
Of particular interest was the finding that three of the pathway- thioridazine were tested in the FOXO1a export assay. All of these
compounds blocked FOXO1a export in 786-O cells (Figure 7A),specific inhibitors belonged to the structural family of phenothi-
azines (Figure 4B; red) (17474Z, 186057T, 5216177), one of raising the possibility that FOXO1a nuclear localization might
be regulated by dopamine receptor signaling. Indeed, phospho-which was trifluoperazine (17474Z). Trifluoperazine, as well as
many other phenothiazines, act as dopamine receptor antago- Akt levels increase when cells are treated with dopamine recep-
tor agonists such as quinpirole and bromocriptine in neuronalnists and are clinically useful as antipsychotic and antiemetic
medications. Like wortmannin, the three phenothiazines relocal- cells (Brami-Cherrier et al., 2002; Kihara et al., 2002).
To investigate whether inhibiting the dopamine receptor canized FOXO1a in 786-O cells to the nucleus, decreased phospho-
Akt levels (Figure 5A), and in two instances blocked export in lead to FOXO1a nuclear retention, structurally unrelated dopa-
mine receptor antagonists were tested in the FOXO1a exportHMEC Myr-p110 cells (Figures 5B and 6).
To determine whether these activities were representative of assay. None of the inhibitors—haloperidol, clozapine, L745870,
CANCER CELL : DECEMBER 2003 469
A R T I C L E
Figure 6. Collective assay results for all lead com-
pounds tested
Compound numbers beginning with “5” are the
ID numbers from ChemBridge and those begin-
ning with “NSC” are the ID numbers from the NCI.
Dark gray denotes the compound scored in the
assay (e.g., blocks FOXO1a or RevGFP export;
inhibits CRM1 in U2OS-RevGFP transfected cells
or in the yeast NLS-NES-GFP export assay; de-
creases phospho-protein levels; blocks cell prolif-
eration). Light gray denotes the compound has
weak activity in the assay and white denotes
the compound showed no activity in the assay.
Black denotes the compound was not tested in
the assay.
or L-stepholidine (L-SPD)—significantly blocked FOXO1a ex- pounds in cells (Mottet et al., 2003; Wei et al., 1983; Yang et
al., 2000). Treatment with the Ca2 chelator, BAPTA-AM, alsoport at concentrations comparable to those previously used to
block dopamine receptors in cells (Dong et al., 1997; Patel et blocked FOXO1a nuclear export at 80 M (Figure 7C). However,
treatment with EGTA, an extracellular calcium chelator, did notal., 1997; Vanhauwe et al., 2000) (Figure 7B). These data strongly
suggest that the dopamine receptor is not the relevant target result in FOXO1a nuclear localization (data not shown). These
data are consistent with the notion that CaM activity regulatedof the phenothiazines with respect to their activity as inhibitors
of FOXO1a export. by intracellular Ca2 regulates FOXO1a subcellular localization.
786-O cell proliferation in presence of compoundsStructurally unrelated CaM inhibitors
block FOXO1a export IC50s were determined for all 42 lead compounds in cell prolifer-
ation studies. In these studies, 786-O cells were grown in 96-Trifluoperazine (17474Z), in addition to its dopamine receptor
antagonist activity, also exhibits inhibitory activity against cal- well plates and treated for 24 hr at decreasing concentrations
of inhibitor serially diluted in complete media from 40 M to 1.25modulin (Levin and Weiss, 1976, 1977), raising the possibility
that it and the phenothiazine class as a whole might interrupt M. Cell viability was determined by correlation with amount
of ATP released when cells were lysed. The results for thesePI3K signaling through calmodulin inhibition. To ask whether
this was the case, Ad-FKHR infected 786-O cells were treated experiments are reported in Figure 6, which also summarizes
the results of the assays for all general export and pathway-for 1 hr with the calmodulin inhibitors W-13, calmidazolium, and
ophiobolin A. Each of these inhibitors relocalized FOXO1a to the specific inhibitors. Most of the inhibitors block cell proliferation;
however, ten compounds exhibited no effect at 40M, includingnucleus (Figure 7C). Moreover, when tested in serial titrations,
FOXO1a export was blocked at concentrations comparable to wortmannin. It is possible these compounds, as with wortman-
nin, are unstable in aqueous solution for an extended period ofthose previously reported for CaM inhibition by these com-
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Figure 7. Trifluoperazine and other phenothi-
azines regulate FOXO1a subcellular localization
through inhibition of CaM
A: 786-O cells infected with Ad-FKHR were
treated with phenothiazine therapeutics. Chlor-
promazine, prochlorperazine, fluphenazine, and
thioridazine all relocalize FOXO1a to the nucleus
at 20 M.
B: Treatment with structurally unrelated dopa-
mine receptor antagonists haloperidol (80 M),
clozapine (20 M), L745870 (80 M), and L-speri-
done (80 M) do not inhibit FOXO1a export sig-
nificantly.
C: Treatment with structurally diverse CaM inhibi-
tors W-13 (40 M), calmidazolium (20 M), and
ophiobolin A (5 M) block FOXO1a export.
BAPTA-AM, an intracellular Ca2 chelator, inhibits
FOXO1a export at 80 M.
time (Stein and Waterfield, 2000; Woscholski et al., 1994). Thus, by the discovery of small molecules specifically targeting key
compounds that localize FOXO1a to the nucleus after 1 hr may cellular proteins, and as such, 19 novel CRM1 export inhibitors
not inhibit proliferation in this 24 hr assay. were identified. Furthermore, a calmodulin-dependent regula-
tory mechanism for controlling FOXO1a localization was discov-
ered. These data suggest that such screens, when conductedDiscussion
in defined systems, can be highly informative and likely compli-
ment traditional in vitro target-based drug screens.A cell-based, visual, chemical genetic screen for small molecule
inhibitors of nuclear export of the transcription factor FOXO1a We have shown that 19 of the compounds that promote
retention of FOXO1a in the nucleus are novel general proteinwas carried out in cancer-derived cells lacking functional PTEN
protein. The utility of this “phenotypic” screen was validated export inhibitors. All 19 block the nuclear export of RevGFP
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and FOXO1a by targeting CRM1, and not by inhibition of other FOXO1a signaling pathway were identified. Among these were
factors in the nuclear transport machinery. Interestingly, all of a novel natural product from marine sponge and several com-
these general inhibitors were isolated from the ChemBridge pounds containing planar aromatic heterocycles similar to the
DiverSetE and make up about half of the total hits from that scaffolds of known kinase inhibitors. These latter compounds
library. While most, if not all, of the general blockers are reactive, may potentially inhibit the activity of kinases involved in Akt
not all of the reactive compounds in the library relocalized signaling or FOXO1a phosphorylation and export. Experiments
FOXO1a in this screen, suggesting that the compounds identi- designed to localize the inhibitory activity of these compounds
fied in the screen exhibit some selectivity for CRM1. Of the 19 within the pathway are ongoing.
compounds in this class, 5219668 is the most potent CRM1 Three of the pathway-specific compounds belong to the
inhibitor (Figure 6). While not as potent as LMB, in some cases structural family of phenothiazines, including trifluoperazine, a
this compound can make a suitable substitute when inhibition known dopamine receptor antagonist and CaM inhibitor. While
of general export is required in experiments. trifluoperazine and several other phenothiazine dopamine re-
Surprisingly, targeting of CRM1 by the general export inhibi- ceptor antagonists relocalized FOXO1a to the nucleus, struc-
tors invariably required the Cys528 residue and the chemical turally unrelated antagonists such as haloperidol, clozapine,
structures suggest that this dependency likely results from cova- L745280, and L-SPD did not. Trifluoperazine and other pheno-
lent interactions. On the other hand, the Cys528 residue is not thiazines such as fluphenazine and chlorpromazine also inhibit
required for CRM1 function and the three-dimensional structure CaM in addition to dopamine receptors. Additional structurally
of CRM1 has not been determined. Therefore, the specific diverse calmodulin inhibitors such as W-13, calmidazolium, and
mechanism by which covalent attack on this residue leads to ophiobolin A robustly relocalized FOXO1a to the nucleus. Fur-
inhibition is not known. The diversity of this new expanded set thermore, treatment of 786-O cells with the intracellular Ca2
of CRM1 inhibitors may shed light on this question. Specifically, chelator, BAPTA-AM, likewise relocalized FOXO1a to the nu-
while it appears that Cys528 binding is required, it may not be cleus, strongly suggesting that calmodulin is a regulator of
sufficient. Thus, determining the structure-activity requirements FOXO1a cellular location. Interestingly, the natural marine
of the reactive compounds scoring in this assay may define any sponge product, B6-7-1, is a bromotyrosine and resembles the
additional requirements. bastadins. Bastadins have been shown to modulate ryanodine
Although S. cerevisiae express a form of CRM1 that does receptors, Ca2 release channels in the sarcoplasmic reticulum
not contain the reactive cysteine residue, S. pombe, human, and (Mack et al., 1994). Though untested, it is possible that B6-7-1
most other organisms do. The subselection of specific reactive
might block Ca2 channels and thereby reduce the intracellular
compounds interacting with CRM1 begs the question of whether
Ca2 concentration. Such an effect, as mimicked by our experi-
the export receptor CRM1 can act as a general sensor for certain
ment with BAPTA-AM, might prevent Ca2 from binding to CaM,types of reactive compounds in nature. For example, cellular
inactivate CaM, and therefore keep FOXO1a nuclear.and transcriptional responses to small molecule toxins present
Reducing intracellular Ca2 levels or inhibiting CaM leadsin the environment might be mediated through CRM1 binding
to inactivation of Akt in PC12 cells (Egea et al., 2001). Similarly,and inactivation. Such inactivation would render CRM1 unable
BDNF activation of Akt is blocked in cells expressing CaM withto export NES-containing proteins and certain transcription fac-
mutant Ca2binding domains (Cheng et al., 2003). The calmodu-tors, including FOXO proteins. Trapped in the nucleus, these
lin inhibitor, W-13, while unable to alter PI3K or Akt kinaseproteins might then enact transcriptional programs resulting in
activity in vitro, decreases phospho-Akt levels in adipocytes ina cell cycle arrest or apoptosis, as examples. In this light, CRM1
a PI3K-independent manner (Egea et al., 2001; Yang et al.,might act as a protector of the cell.
2000). Together, these suggest the presence of a CaM-depen-The utility of LMB as a therapeutic has been explored with
dent, PI3K-independent path to Akt activation. Finally, Ca2/respect to the role of CRM1 in regulating p53 localization. For
calmodulin-dependent protein kinase kinase (CaM-KK) canexample, trapping p53 in the nucleus with LMB results in its
phosphorylate Akt and SGK1 through a Ca2/CaM signalingreactivation and transduction of its biological responses includ-
pathway (Imai et al., 2003; Yano et al., 1998). Thus, one possibil-ing cellular apoptosis (Hietanen et al., 2000; Lain et al., 1999a),
ity is that FOXO1a cellular localization and activity might beleading some to propose targeting nuclear transport as a means
regulated by a Ca2/CaM signaling cascade that results in theof controlling cancer growth (Kau and Silver, 2003; Lain et al.,
activation of CaM-KK and phosphorylation of both Akt and1999b). In phase I clinical trials, however, targeting CRM1 with
SGK1 by CaM-KK.LMB was associated with profound toxicity (Newlands et al.,
A schematic of the pathway depicting the site of action for1996). Cells expressing mutant CRM1 are resistant to LMB;
the compounds that we have characterized thus far is shownthus, it is critical to understand whether patient-related toxicity
in Figure 8. Several of the compounds might prove to be leadsis target related or due to non-CRM1, off-target effects of LMB.
for potential anticancer drug development including trifluoper-If patient-related toxicity is linked to non-CRM1 effects of LMB,
azine and 5233705. There is an ongoing vigorous debate on thethen the possible lower toxicity of some of the compounds
virtues or perils of cell-based screening. This particular screenidentified in this screen could potentially guide the preclinical
proved robust, facile, highly amenable to academic scaledevelopment of CRM1 inhibitors with improved therapeutic
screens, and more importantly, elucidated previously undiscov-index.
ered export and PI3K pathway inhibitors. Furthermore, we haveOne of the inherent strengths of our FOXO1a-based screen
determined the specific molecular mechanism for inhibition ofis the ability to identify both general export inhibitors and more
representative compounds within both classes of inhibitors,specific effectors of the signaling pathways that promote
leading to the discovery of novel CRM1 inhibitors and revealingFOXO1a movement and activity. Thus, 23 small molecule inhibi-
tors of FOXO1a export that appear to act in the PI3K/Akt/ the role of CaM in regulating PI3K signaling to FOXO1a. Experi-
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Figure 8. Target sites of compounds identified from the screen
Two inhibitors have targets located upstream of PI3K, 16 compounds target somewhere between PI3K and Akt inclusively, two inhibitors have targets
downstream of Akt, 19 inhibitors target CRM1, and three inhibitors target CaM and implicate CaM as a novel regulator of FOXO1a activity and subcellular
localization.
p110 and HMEC-vector, were previously described in Zhao et al. (2003).ments are currently underway to identify the targets of the re-
Cells were grown in mammary epithelial basal medium (MEBM, BioWhittaker)maining pathway-specific compounds.
supplemented with mammary epithelial growth medium (MEGM, BioWhit-
taker) consisting of hydrocortisone, EGF, insulin, and bovine pituitary extract.Experimental procedures
Wild-type yeast PSY580 and CRM1 mutant yeast PSY1969 were trans-
formed with the NLS-NES-GFP plasmid using a standard transformationMaterials
protocol. Transformants were selected on ura dropout plates.LMB, wortmannin, and haloperidol were purchased from Sigma. L-SPD,
W-13, calmidazolium, and ophiobolin A were purchased from Calbiochem.
Adenovirus constructionBAPTA-AM was purchased from Molecular Probes. L754870 was purchased
Ad-FKHR was generated with the pAD-Easy system (He et al., 1998). Infrom Tocris. Clozapine was purchased from Alexis Corp. Phenothiazine
brief, linearized shuttle plasmid containing the cDNA for FLAG-FOXO1a wastherapeutics thioridazine, fluphenazine, chlorpromazine, and prochlorpera-
cotransfected with pAdEasy-1 into BJ5183 cells. After isolation, recombinantzine were purchased from ICN Biomedicals, Inc.
adenoviral DNA was restriction digested with PacI and transfected into 293Lead compounds from the screen were ordered from ChemBridge Corp.
cells. Infectious adenovirus was amplified in 293 cells. Purified virus wasor requested from the NCI. The pRev(1.4)-GFPPKI NES plasmid was a gift
isolated by freeze-thaw extraction followed by CsCl gradient purificationfrom Beric Henderson and its construction described in Henderson and
and titred by plaque lysis.Eleftheriou (2000). The CRM1-Cys528Ser mutant plasmid, pXHCK1, was a
gift from Minoru Yoshida and previously described in Akakura et al. (2001).
FOXO1a export assay in 786-O and HMEC cellsThe NLS-NES-GFP plasmid (pPS1372) was previously described in Taura
786-O cells were seeded onto 384-well, black, clear-bottom plates (Costar)et al. (1998).
at a density of2500–3000 cells/well in 50 l complete media. After incuba-
tion at 37C, 5% CO2 for 2–3 hr, cells were infected with Ad-FKHR andCell culture and yeast strains
incubated for 24 hr. Small molecule compounds were serially diluted 1:2786-O and U2OS-RevGFP cells were grown and maintained in Dulbecco’s
starting from 80 M in a separate 384-well plate using a 16-channel pipettemodified Eagle’s medium (DMEM) containing 10% Fetal Clone (Clonetech)
(ThermoLabsystems) in DMEM. Media were aspirated from infected cellsand 100 g/ml penicillin-streptomycin at 37C, 5% CO2. U2OS-RevGFP
using a 24-channel wand before diluted small molecules were transferredcells were established by transfecting U2OS cells with pRev(1.4)-GFPPKI
onto cells. Cells were incubated for1 hr before 3.7% formaldehyde fixation.NES using FuGENE 6 reagent according to the manufacturer’s protocol
Fixed cells were then stained with M5 anti-FLAG antibody (Sigma) followed(Boehinger Mannheim). Stable clones were selected in complete media con-
taining 400 g/ml G418. Human mammary eptithelial cells, HMEC-Myr- by washing with PBS three times and staining with Alexa Fluor 594 goat
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anti-mouse antibody (Molecular Probes) and Hoechst 33258 (Sigma). Both concentrations were determined using Bradford reagent (Bio-Rad) and ali-
antibodies, M5 and Alexa Fluor 594, were diluted 1:1000 in PBS/0.2%TX- quots of lysates with equal amounts of protein were resolved by SDS-PAGE
100/5%FBS. For cell counts, at least 200 cells exhibiting nuclear, nuclear and transferred onto Immobilon-P membranes (Millipore). Membranes were
and cytoplasmic, or cytoplasmic staining were counted from three separate blocked in 5% powdered milk in PBST (PBS, 0.2% Tween-20), incubated
images. Percentages of N, NC, and C cells were calculated and standard overnight at 4C in phospho-Ser473-Akt antibody (Cell Signaling) diluted
deviations determined. 1:1000 in PBST containing 5% BSA. Phospho-Ser473-Akt levels were de-
HMEC’s were treated similarly except they were seeded at a density of tected using anti-rabbit HRP diluted 1:5000 in 5% milk/PBST followed by
3500 cells/well and incubated overnight before infection with Ad-FKHR Western Lightning chemiluminescence reagent (PerkinElmer). Blots were
virus. Compounds were diluted in MEBM supplemented with MEGM. stripped in stripping buffer (100 mM glycine, HCl/pH 2.5), washed twice in
PBST, and blocked in PBST containing 5% milk before re-probing with pan
High-throughput screen Akt antibody (Cell Signaling) diluted 1:1000 in PBST/5% BSA. Phospho-
Cell-based screening was performed at the Institute for Chemistry and Cell SGK (Upstate) was diluted 1:200 in PBST/5%BSA. For phospho-Thr308-
Biology (http://iccb.med.harvard.edu). 786-O cells were seeded onto black, Akt (Cell Signaling) immunoblots, membranes were blocked in 4% milk in
clear-bottom, 384-well plates at 2500–3000 cells/well in 50 l complete TBST and secondary anti-rabbit HRP was diluted 1:3000 in 2% milk/TBST.
media using a Multidrop liquid dispenser (Labsystems). Cells were then
incubated for 3 or 17 hr before infection with Ad-FKHR for 24 hr. Com- Cell viability assay
pounds from the ChemBridge DiverSetE (ChemBridge Corp.) and the NCI 786-O cells were seeded onto opaque, white, 96-well plates (Costar) at
Structural Diversity Set (NCI) were kept at a stock concentration of 5 mg/ml 2500 cells/well density and incubated for 24 hr. Compounds were serially
(10 mM) in DMSO. 100 nl of each compound, as well as those from the diluted 1:2 from 40 M to 1.125 M on a different 96-well plate in serum-
NCI marine extract plate, were transferred to cells by a solid 384-pin array containing media. 100 l of each dilution was transferred onto cells after
device attached to a robotic arm. Cells were then incubated for 1 hr at removal of media. Cells were incubated with inhibitors for 24 hr. Cell
37C, 5% CO2. Formaldehyde fixation and antibody staining were performed viability was assayed using CellTiter-Glo luminescent cell viablilty assay
as described in the FOXO1a export assay. (Promega) following the manufacturer’s protocol.
Digital images of cells in each well were acquired using an automated
fluorescence microscope equipped with a Plan Fluor 10X NA 0.3 objective Acknowledgments
(Nikon) and Metamorph software (Universal Imaging). FOXO1a subcellular
localization was scanned visually for each imaged plate. We are grateful to the ICCB for advice and help with the screen, in particular
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at 4500 cells/well in 50 l complete media. Cells were allowed to attach used in this study. We thank Eric Smith for the preparation of Figures 1C,
and grow overnight before compound treatment. Compounds were serially 3A, and 8. This work was supported by grants from the NIH (GM36373) and
diluted 1:2 starting from 40 M in a separate 384-well plate in DMEM. Media the Barr Investigator Program to P.A.S. W.R.S. was supported by the NCI
were aspirated from cells before the diluted compounds were transferred (CA85912) and the Damon-Runyon Lilly Clinical Investigator Award. T.M.R.
onto cells. Cells were incubated with compound for 1 hr before fixation was supported by the NIH (CA30002, CA89021) and J.C. and F.S. by the
with 3.7% formaldehyde and nuclei staining with Hoechst 33258. For the
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